Atossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200 Day Moving Average – Here’s Why

Atossa Therapeutics, Inc. (NASDAQ:ATOS) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.24 and traded as low as $0.76. Atossa Therapeutics shares last traded at $0.82, with a volume of 572,873 shares changing hands.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a report on Thursday, January 30th. Ascendiant Capital Markets raised their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. Finally, StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, November 18th.

Atossa Therapeutics Trading Up 7.1 %

The stock’s 50-day moving average price is $0.98 and its 200-day moving average price is $1.24. The company has a market cap of $103.17 million, a P/E ratio of -3.73 and a beta of 1.24.

Institutional Trading of Atossa Therapeutics

Hedge funds have recently bought and sold shares of the business. Intech Investment Management LLC purchased a new stake in Atossa Therapeutics in the 3rd quarter valued at $29,000. Gallagher Capital Advisors LLC bought a new position in Atossa Therapeutics during the fourth quarter valued at $25,000. SG Americas Securities LLC increased its position in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Atossa Therapeutics in the third quarter valued at $75,000. Finally, XTX Topco Ltd lifted its position in shares of Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after buying an additional 24,951 shares during the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.